Innovent Biologics Equity 2024

Innovent Biologics Aktienanalyse

What does Innovent Biologics do?

Innovent Biologics Inc. is an innovative biopharmaceutical company that focuses on the discovery, development, and commercialization of world-leading biological therapies. The company was founded in 2011 by a group of outstanding scientists who already had extensive experience in biological research and development. Since then, Innovent Biologics Inc. has achieved many successes and has become a significant player in the biopharmaceutical industry. Innovent Biologics' business model is based on the use of cutting-edge technology and collaboration with partners to develop and bring innovative biopharmaceuticals to the market. The company utilizes a platform technology based on a combination of protein production and antibody development to provide a strong foundation for its innovative pipeline of therapeutics. Innovent Biologics specializes in three main areas: cancer therapy, autoimmune diseases, and ophthalmology. The company has developed an impressive number of product candidates to meet the need for innovative therapeutics in these areas. In the field of cancer therapy, Innovent Biologics specializes particularly in the treatment of lung tumors. The company has successfully developed tyrosine kinase inhibitors targeting important therapy targets. Additionally, the company has also developed antibodies against cancer that stimulate the patient's immune system to fight tumor cells. Innovent Biologics is also a leader in the development of drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. By identifying highly specific antibodies with therapeutic potential, the company has developed a pipeline of promising drug candidates. In the field of ophthalmology, Innovent Biologics has achieved remarkable successes. The company has developed an innovative therapeutic antibody platform specifically targeting the treatment of eye diseases. This platform allows for the optimization of the drug to better suit the eye and achieve higher efficacy. Innovent Biologics has already discovered several antibody candidates that have produced promising clinical results. In addition to its product candidates, Innovent Biologics has also formed partnerships with other industry players. The company collaborates closely with other biopharmaceutical companies to jointly develop and market innovative therapeutics. Overall, Innovent Biologics Inc. has built an impressive track record and experience in a relatively short period. It is a leading player in the development of biopharmaceuticals that have the potential to revolutionize the healthcare industry. The company has a strong pipeline of product candidates in various therapy areas, supported by innovative platform technology. Innovent Biologics is able to further expand its work through close collaboration with partners and a variety of collaborators. Innovent Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Innovent Biologics's Equity

Innovent Biologics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Innovent Biologics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Innovent Biologics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Innovent Biologics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Innovent Biologics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Innovent Biologics stock

What is the equity of Innovent Biologics this year?

Innovent Biologics has equity of 12.53 B CNY this year.

What was the equity of Innovent Biologics compared to the previous year?

The equity of Innovent Biologics has increased/decreased by 16.75% increased compared to the previous year.

What impact does a high equity have on investors of Innovent Biologics?

A high equity is advantageous for investors of Innovent Biologics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Innovent Biologics?

A low equity can be a risk for investors of Innovent Biologics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Innovent Biologics affect the company?

An increase in equity of Innovent Biologics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Innovent Biologics affect the company?

A reduction in equity of Innovent Biologics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Innovent Biologics?

Some factors that can affect the equity of Innovent Biologics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Innovent Biologics so important for investors?

The equity of Innovent Biologics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Innovent Biologics take to change the equity?

To change equity, Innovent Biologics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Innovent Biologics pay?

Over the past 12 months, Innovent Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Innovent Biologics is expected to pay a dividend of 0 CNY.

What is the dividend yield of Innovent Biologics?

The current dividend yield of Innovent Biologics is .

When does Innovent Biologics pay dividends?

Innovent Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Innovent Biologics?

Innovent Biologics paid dividends every year for the past 0 years.

What is the dividend of Innovent Biologics?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Innovent Biologics located?

Innovent Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Innovent Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Innovent Biologics from 7/12/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Innovent Biologics pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Innovent Biologics in the year 2023?

In the year 2023, Innovent Biologics distributed 0 CNY as dividends.

In which currency does Innovent Biologics pay out the dividend?

The dividends of Innovent Biologics are distributed in CNY.